Description
There are already multiple cannabinoids that are FDA-approved to treat specific medical conditions. While some have been around for decades, plenty more in the pipeline of late-phase studies. In this discussion, we will dive deeper into the weeds of understanding the pharmacology and clinical care concerns of current prescription cannabinoids with respect to FDA approvals, dosage, drug interactions, and side effects. We will then discuss possible mechanistic endocannabinoid system (ECS) targets of future pharmaceutical and commercial cannabinoid products.